Evosep Launches High-Throughput Proteomics Platform Eno and Expands SCIEX Partnership at ASMS 2025
核心洞察
Evosep (搜索) unveiled the Evosep Eno (搜索), a high-throughput separation platform that can analyze over 500 samples per day and identify close to 7,000 proteins with 40% improved performance.
The new platform enables analysis of more than 2,000 proteins per minute while maintaining industry-leading system-to-system and lab-to-lab reproducibility for multi-site studies.
Evosep (搜索) strengthened its strategic partnership with SCIEX (搜索) through a reseller agreement, allowing SCIEX to offer the Evosep Eno (搜索) alongside their mass spectrometers to pharmaceutical customers.
Evosep (搜索), a global leader in proteomics solutions, announced the launch of the Evosep Eno (搜索) at the ASMS 2025 conference in Baltimore, marking a significant advancement in LC-MS based proteomics technology. The robust, high-throughput separation platform is designed for next-generation workflow integration and promises to transform drug discovery and translational research capabilities for pharmaceutical and biotech industries.
Revolutionary Performance Capabilities
The Evosep Eno (搜索) delivers unprecedented throughput and analytical capabilities that address critical bottlenecks in proteomics research. According to Prof. Jesper V. Olsen from the University of Copenhagen, "The new Evosep Eno will make a big impact in the next generation of LC-MS based proteomics. With the new Evosep Eno we can analyze more than 500 samples per day which was impossible before and identify close to 7000 proteins and quantify 70,000 precursors, so that's absolutely amazing."
The platform achieves more than 2,000 proteins per minute at 500 samples per day, enabling unmatched throughput for large-scale studies while accelerating biomarker discovery and clinical research without compromising data quality. This represents a 40% improvement in performance while simultaneously increasing accuracy and precision in protein quantification.
Enhanced Reproducibility and Standardization
The Evosep Eno (搜索) addresses a critical challenge in proteomics research by delivering industry-leading system-to-system and lab-to-lab reproducibility. This consistency across different systems and locations provides trustworthy data for multi-site studies, supporting academic research centers, drug developers, and contract research organizations.
"The Evosep Eno (搜索) is a key component of the next generation LC-MS based proteomics workflows. Its capabilities will empower researchers to uncover new insights and drive progress in drug discovery and translational research," said Nicolai Bache, VP Proteomics Research at Evosep (搜索).
The platform incorporates standardized workflows with integrated consumable solutions that simplify and streamline processes, increasing efficiency and reducing errors in proteomics analyses.
Strategic Partnership Expansion with SCIEX
Concurrent with the Eno launch, Evosep (搜索) announced a strengthened strategic partnership with SCIEX (搜索), a global leader in analytical instrumentation. The companies have entered into a reseller agreement that enables SCIEX to offer the Evosep Eno (搜索) alongside their mass spectrometers to customers in the pharmaceutical and biotech sectors.
This collaboration creates synergy between Evosep (搜索) and SCIEX (搜索)'s technologies and industry expertise, providing comprehensive solutions for drug development pipelines. The partnership enables pharmaceutical companies to analyze a wider range of drug modalities more efficiently and at larger scale.
"This strengthened partnership with SCIEX (搜索) enables us to deliver more robust, scalable solutions for the pharma and biotech industries, directly addressing their need for high-throughput, high-sensitivity proteomics," said Eric Grumbach, VP of Business Development - Pharma at Evosep (搜索). "As we continue to grow, these partnerships provide coherent solutions that enable our customers to make proteomics a powerful tool in the development of life-saving drugs."
Impact on Drug Development
The Evosep Eno (搜索) platform is positioned to significantly accelerate drug discovery and translational research programs by enabling researchers to gain deeper insights into the proteome quickly and accurately. The technology addresses the evolving needs of pharmaceutical and biotech companies by providing end-to-end solutions that support the analysis of diverse drug modalities.
Evosep (搜索)'s mission focuses on improving quality of life and patient care by radically innovating protein-based clinical diagnostics through collaborations with world-leading scientists. The company aims to develop technologies and solutions that make sample separation 100 times more robust and 10 times faster than current alternatives.
The Evosep Eno (搜索) is classified as General Laboratory Equipment, and Evosep (搜索) presented the platform at Booth #309 during the ASMS 2025 conference, where media members were invited to discuss the future of proteomics workflows.